REFRESHER NEWS!

*Quizartinib,, an investigational TKI
show promises in FLT3 AML allowing time, with some effectiveness, for stem cell transplant

*A study confirm that Hct should be maintained below 45% in Polycythemia Vera as patient above this percentage had four-fold higher incidence of thrombotic events, a study confirmed.

*Once again, and repetition is good, Ibrutinib, a Bruton's TKI show appreciable activity in CLL alone or in combination with Rituxan.

* From Smita Bathia, MD
we learned that "genes involved in the metabolism of Anthracyclines include CBR1, CBR3,NQO1, MRP1,2
defense for Oxidative stress that can cause damage to heart cells, NCF4 RAC2 CYBA,SOD
Blood pressure and heart rate regulation AGT, AGTR1, ACE, ADRB1
Iron Homeostasis HFE"

This will prompt to plan a discussion of gene Nomenclature relevant to these genes!

*Adding Vorinostat to Chemotherapy during transplantation process reduces the incidence of Acute GVHD.
*Just a rminder again, Alterations in CYP2D6 affects efficacy of Tamoxifen.